Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising candidate for cancer therapy because of its relative tumor selectivity. However, many cancers including pancreatic cancer remain resistant towards TRAIL. To develop TRAIL for cancer therapy of pancreatic carcinoma, it will therefore be pivotal to elucidate the molecular mechanisms of TRAIL resistance. Here, we identify X-linked inhibitor of apoptosis (XIAP) as a regulator of TRAIL sensitivity in pancreatic carcinoma cells. Full activation of effector caspases, loss of mitochondrial membrane potential and cytochrome c release following TRAIL treatment were markedly impaired in pancreatic carcinoma cell lines, which poorly responded to TRAIL (PaTuII, PancTu1, ASPC1, DanG), compared to TRAIL-sensitive Colo357 pancreatic carcinoma cells. Stable downregulation of XIAP by RNA interference significantly reduced survival and enhanced TRAIL-induced apoptosis in pancreatic carcinoma cells. Also, downregulation of XIAP significantly increased CD95-induced cell death. Importantly, knockdown of XIAP strongly inhibited clonogenicity of pancreatic cancer cells treated with TRAIL indicating that XIAP promotes clonogenic survival of pancreatic carcinoma cells. Thus, our findings for the first time indicate that targeting XIAP represents a promising strategy to enhance the antitumor activity of TRAIL in pancreatic cancer, which has important clinical implications.
Introduction
Pancreatic cancer is one of the leading causes of cancer deaths in the Western World with steadily raising numbers (Parker et al., 1997) . Despite intensive therapies, resistance of pancreatic cancer to current treatment protocols still constitutes one of the most challenging problems in oncology (Wolff et al., 2000; Schneider et al., 2005) . Thus, novel treatment approaches are necessary to improve the dismal prognosis of this disease. The aggressive pancreatic cancer phenotype is the result of a variety of genetic and epigenetic alterations leading to deregulation of intracellular signaling pathways (Bardeesy and DePinho, 2002) . For example, pancreatic cancer cells become refractory to undergo apoptosis, the cell's intrinsic suicide program critical for tissue homeostasis (Westphal and Kalthoff, 2003) . Therefore, current attempts to improve the survival of pancreatic cancer patients will have to include strategies that specifically target tumor cell resistance to apoptosis.
Cell death by apoptosis plays a pivotal role in various physiological or pathological conditions and has also been implied to mediate therapy-induced cytotoxicity, for example following chemotherapy, g-irradiation or immunotherapy (Hengartner, 2000; Fulda and Debatin, 2004a, b) . Apoptosis pathways may be initiated through different entry sites, such as death receptors or mitochondria, resulting in activation of effector caspases (Fulda and Debatin, 2004b) . Ligation of death receptors of the tumor necrosis factor (TNF) receptor superfamily such as CD95 (APO-1/Fas) or the agonistic TNFrelated apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2 by their cognate ligands or agonistic antibodies results in caspase-8 activation which induces direct cleavage of downstream effector caspases (Ashkenazi, 2002) . The mitochondrial pathway is engaged by the release of apoptogenic factors such as cytochrome c, apoptosis inducing factor (AIF), second mitochondria-derived activator of caspase (Smac)/direct IAP-binding protein with low isoelectric point (PI) (DIABLO) or Omi/high temperature requirement protein A2 (HtrA2) from mitochondria into the cytosol triggering caspase-3 activation as a result of formation of the cytochrome c/Apaf-1/caspase-9-containing apoptosome complex (Saelens et al., 2004) . Signals originating from death receptors may be linked to mitochondria via Bcl-2 family proteins such as Bid, which causes cytochrome c release upon cleavage by caspase-8, thereby initiating a mitochondrial amplification loop (Cory and Adams, 2002) . This mitochondrial amplification loop is of special relevance for type II cells, for example pancreatic carcinoma, which depend on the mitochondrial pathway to properly respond to death receptor-triggered apoptosis (Fulda et al., 2002a, b) .
The concept of inducing apoptosis in cancer cells by ligation of death receptors is of special interest for cancer therapy, as death receptors are directly linked to the cell's intrinsic death program (Ashkenazi, 2002) . The death-inducing ligand TRAIL is a prime candidate for cancer therapy, because it has been reported to induce apoptosis in a wide spectrum of cancer cell lines with no or minimal toxicity on normal human cells (LeBlanc and Ashkenazi, 2003) . Also, TRAIL exhibited potent tumoricidal activity in several xenograft models in vivo (LeBlanc and Ashkenazi, 2003) . However, various cancers proved to be refractory towards treatment with TRAIL, for example, because of aberrant activation of antiapoptotic programs (Fulda and Debatin, 2004b) . For example, many human cancers harbor high levels of 'Inhibitor of apoptosis proteins' (IAPs) such as X-linked inhibitor of apoptosis (XIAP), cellular inhibitor of apoptosis protein 1 (cIAP1), cIAP2, survivin or livin, which have been associated with treatment resistance and dismal prognosis (Salvesen and Duckett, 2002) . IAPs block apoptosis at a central point by binding to and inhibiting effector caspases (Salvesen and Duckett, 2002) .
The majority of pancreatic carcinoma cell lines have been reported to be refractory towards treatment with TRAIL despite expression of the essential components of the TRAIL signaling system (Hinz et al, 2000; Ibrahim et al., 2001; Satoh et al., 2001; Trauzold et al., 2001; Gerhard et al., 2002) . However, the molecular determinants, which confer resistance of pancreatic carcinoma cells towards TRAIL, have not yet been fully elucidated. Therefore, in search for novel strategies to overcome resistance of cancers such as pancreatic carcinoma, the present study was designed to investigate regulation of TRAIL-induced apoptosis and the involvement of IAPs in pancreatic carcinoma.
Results
Although pancreatic carcinoma cells have been reported to express the molecules of the TRAIL signaling machinery, most pancreatic carcinoma cell lines turned out to remain resistant towards TRAIL (Hinz et al., 2000; Ibrahim et al., 2001; Satoh et al., 2001; Trauzold et al., 2001; Gerhard et al., 2002) . However, the molecular mechanisms responsible for TRAIL resistance of pancreatic carcinoma cells have not yet been elucidated in detail.
TRAIL-induced cell death in pancreatic carcinoma cells
To gain insight into the regulation of TRAIL-induced cell death in pancreatic carcinoma cells, we analysed the effect of TRAIL on cell viability and apoptosis in a panel of human pancreatic carcinoma cell lines. The majority of pancreatic carcinoma cell lines (nine of 12 cell lines) were relatively resistant to TRAIL-induced apoptosis as determined by analysis of DNA fragmentation, showing o30% apoptosis upon treatment with 10 ng/ml TRAIL for 72 h (Figure 1a) . By comparison, TRAIL efficiently triggered cell death in Colo357, MiaPaCa2 and Capan1 pancreatic carcinoma cells (>70% apoptosis upon treatment with 10 ng/ml TRAIL for 72 h, Figure 1a ) or in TRAIL-sensitive Jurkat leukemia cells (data not shown). Increasing TRAIL concentrations up to 100 ng/ml did not revert the poor responsiveness of the majority of pancreatic carcinoma cell lines towards TRAIL (Figure 1a) . Similarly, when cell viability was assessed by 5] dimethylthiazol-2, 5-diphenyltetrazolium bromide) assay, only Colo357, MiaPaCa2 and Capan1 cells readily responded to TRAIL treatment, whereas comparatively high TRAIL concentrations were required to induce loss of viability in most pancreatic carcinoma cell lines (Figure 1b) . In some pancreatic carcinoma cell lines, we observed a slight increase in cell viability upon treatment with low concentrations of TRAIL (Figure 1b) in line with our previous findings that TRAIL may trigger proliferation under certain circumstances (Ehrhardt et al., 2003) . Based on these studies, we selected PaTuII, PancTu1, ASPC1 and DanG pancreatic carcinoma cells, which were relatively resistant towards TRAIL, and Colo357 as a prototype TRAIL-sensitive cell line to identify molecular (Hinz et al., 2000; Trauzold et al., 2003) . This indicates that resistance to TRAIL is presumably caused by mechanisms acting further downstream in the TRAIL signaling pathway.
Impaired mitochondrial perturbations in TRAIL-resistant pancreatic carcinoma cells As pancreatic carcinoma cells have been reported to represent type II cells, which depend on the mitochondrial pathway to execute death receptor-triggered apoptosis (Hinz et al., 2000) , we analysed activation of the mitochondrial pathway following stimulation with TRAIL. TRAIL induced only a minor drop of mitochondrial membrane potential in PaTuII, PancTu1, ASPC1 and DanG pancreatic carcinoma cells, which poorly responded to TRAIL ( Figure 3a ). In contrast, TRAIL rapidly triggered loss of mitochondrial membrane potential in TRAIL-sensitive Colo357 pancreatic carcinoma cells ( Figure 3a ). In addition, we assessed the release of cytochrome c from mitochondria into the cytosol by flow cytometry. Following treatment with TRAIL, there was only a minor release of cytochrome c into the cytosol in PaTuII, PancTu1, ASPC1 and DanG 
Expression of IAPs in pancreatic carcinoma cells
Based on our findings indicating that activation of the caspase cascade was inhibited at the level of effector caspases in pancreatic carcinoma cells, we next analysed expression of IAPs, endogenous inhibitors of caspases, which are known to antagonize activity of effector caspases. Western blot analysis revealed that XIAP, cIAP2 and survivin were expressed at high levels in pancreatic carcinoma cell lines ( Figure 5 ). In addition to IAPs, the endogenous IAP antagonist Smac was also expressed in all pancreatic carcinoma cell lines ( Figure 5 ).
Stable downregulation of XIAP by shRNA in pancreatic carcinoma cells
The pattern of caspase cleavage in PaTuII and PancTu1 pancreatic carcinoma cells, for example, cleavage of caspase-8 and partial cleavage of caspase-3 with no significant increase in caspase-3 enzymatic activity and only minimal cleavage of the prototype caspase-3 substrate PARP (Figure 4 ) suggested that activation of the caspase cascade was blocked at the level of effector caspases in these cells. In support of this notion, we found high expression levels of IAPs in these cells ( Figure 5 ). Thus, our data obtained so far pointed to a possible role of IAPs in blocking activity of effector caspases in these cells. To test this hypothesis, we decided to target IAP expression by an RNA interference (RNAi) approach. For these studies, we selected XIAP, as it is considered to exert the most pronounced antiapoptotic activity among the IAP family proteins (Salvesen and Duckett, 2002 (Figure 7a and b) . In addition, we tested RNAi sequence 1548, which was also effective in reducing XIAP protein expression (Figure 6) . Similarly, knockdown of XIAP by this independent Moreover, we wished to explore in more detail whether or not downregulation of XIAP sensitized for induction of apoptosis by assessing DNA fragmentation as one of the biochemical hallmarks of apoptosis. Downregulation of XIAP expression significantly sensitized PaTuII and PancTu1 pancreatic carcinoma cells for TRAIL-induced apoptosis compared to cells expressing nonsense shRNA (Supplementary Figure 2) . Of note, expression of nonsense shRNA had no detectable effect on cell viability or apoptosis alone or in combination with TRAIL compared to the empty vector in both pancreatic carcinoma cell lines (data not shown). To assess whether or not the apoptosis sensitizing effect of XIAP downregulation was restricted to the deathinducing ligand TRAIL, we extended our studies to another death receptor system, CD95. Interestingly, downregulation of XIAP expression also significantly sensitized both PaTuII and PancTu1 pancreatic carcinoma cells to CD95-induced cytotoxicity (Figure 8 ). These data suggest that XIAP is an important regulator of death receptor-induced cell death in pancreatic carcinoma cells.
Furthermore, to assess whether knockdown of XIAP expression only has an effect on the kinetics of deathreceptor-induced cell death or on clonogenic survival of tumor cells as well, we performed clonogenic assays. Importantly, knockdown of XIAP cooperated with TRAIL to reduce clonogenic growth of PaTuII, PancTu1 and also Colo357 pancreatic carcinoma cells (Figure 9 ), demonstrating that XIAP antagonism inhibited long-term survival of pancreatic carcinoma cells in response to TRAIL treatment.
Discussion
Despite aggressive treatment regimens, patients with the diagnosis of pancreatic cancer still have a dismal prognosis (Schneider et al., 2005) . Current attempts to improve the survival of these patients largely depend on novel strategies designed to overcome the intrinsic resistance of pancreatic cancer to established therapies (Wolff et al., 2000) . The idea to directly trigger apoptosis in cancer cells by stimulating death receptors at the cell surface has gained considerable attention, as these receptors have a direct link to the cell's intrinsic death machinery (Ashkenazi, 2002) . TRAIL, a member of the TNF family of death-inducing ligands, is a prime candidate for cancer therapy, because it almost selectively induces apoptosis in a wide spectrum of cancers with no or minimal toxicity on normal human cells (LeBlanc and Ashkenazi, 2003) . Agents triggering TRAIL receptors, for example, agonistic TRAIL receptor antibodies or recombinant TRAIL, have been extensively studied in preclinical models and are currently under investigation in clinical trials (LeBlanc and Ashkenazi, 2003) . However, the potential application of TRAIL for cancer therapy is hampered by the TRAIL-induced apoptosis in pancreatic cancer M Vogler et al fact that despite expression of both agonistic TRAIL receptors high concentrations of TRAIL are necessary to induce cell death, which may be caused by the dominance of antiapoptotic programs (Fulda and Debatin, 2004a) . Therefore, further insights into the molecular determinants of TRAIL-induced apoptosis are pivotal to improve outcome of TRAIL treatment in pancreatic carcinoma. Here, we provide convincing evidence that XIAP is involved in regulating sensitivity of pancreatic carcinoma cells towards TRAIL. Activation of the caspase cascade was blocked at the level of complete activation of effector caspases such as caspase-3 in pancreatic carcinoma cell lines poorly responding to TRAIL. XIAP as well as cIAP2 and survivin were expressed at high levels in pancreatic carcinoma cell lines. Stable downregulation of XIAP by shRNA in pancreatic carcinoma cells significantly reduced survival of pancreatic carcinoma cells upon treatment with TRAIL and enhanced TRAIL-induced apoptosis. Importantly, knockdown of XIAP also strongly inhibited clonogenicity of pancreatic cancer cells treated with TRAIL, demonstrating that XIAP has an impact on long-term survival. Thus, our findings suggest that targeting XIAP represents a promising novel strategy to enhance TRAIL-induced cell death in pancreatic carcinoma.
While previous studies have addressed the impact of IAPs on apoptosis regulation in other cancers, for example in melanoma, breast, lung, bladder, ovarian or colon carcinoma (Sasaki et has not yet been answered. Our study is the first report that has addressed the effect of stable downregulation of XIAP by shRNA on pancreatic cancer cell survival. We observed no compensatory changes in the levels of other IAPs upon stable reduction of XIAP levels by shRNA. Also, we found that knockdown of XIAP expression on its own did not induce activation of caspases or cell death under standard culture conditions and in the absence of externally applied apoptotic stimuli. Similarly, we previously found that Smac peptides enhanced TRAIL-or doxorubicin-induced apoptosis without cytotoxicity when administered alone (Fulda et al., 2002b) . Thus, an apoptotic trigger was required in pancreatic carcinoma cells for caspase activation and cell death when XIAP was downregulated. Accordingly, knockdown of XIAP expression strongly enhanced cell death triggered by ligation of death receptors, for example, by TRAIL or agonistic anti-CD95 antibodies, over a wide range of concentrations and time points. Also, knockdown of XIAP strongly reduced clonogenic growth of pancreatic carcinoma cells showing that it impaired long-term tumor cell survival. This sensitization for TRAIL-or CD95-induced apoptosis by XIAP knockdown was pronounced also when compared to data reported for other cancers (Amantana et al., 2004; Chawla-Sarkar et al., 2004) . As we observed no strict correlation between XIAP expression and TRAIL responsiveness in the pancreatic carcinoma cell lines investigated, our findings indicate TRAIL-induced apoptosis in pancreatic cancer M Vogler et al that additional factors besides XIAP may be involved in regulating apoptosis sensitivity in pancreatic carcinoma. Thus, the composition of pro-and antiapoptotic factors rather than a single molecule may ultimately determine the susceptibility of pancreatic cancer cells to undergo apoptosis. However, as downregulation of XIAP did not only increase TRAIL-induced cell death in the relatively resistant cell lines PaTuII and PancTu1 but also in the rather sensitive cell line Colo357, our findings indicate that XIAP is an important regulator of TRAIL-induced apoptosis in pancreatic carcinoma cells with high XIAP expression. Also, a differential subcellular localization of XIAP, depending on the cell type, may contribute to regulate its ability to prevent cell death (Vischioni et al., 2006) . There is mounting evidence that cancer cells have an intrinsic drive to apoptosis that is held in check by IAPs (Yang et al., 2003) . To this end, high basal levels of caspase-3 and caspase-8 activities in the absence of apoptosis were detected in various tumor cell lines as well as in cancer tissues, including pancreatic carcinoma (Yang et al., 2003) . Simultaneously, high levels of IAPs were present in these tumor cells suggesting that upregulated IAP expression counteracted the high basal caspase activity selectively in tumor cells (Yang et al., 2003) . Thus, IAPs may serve as key molecular targets for the development of cancer cell-selective therapeutics. Ongoing studies in our laboratory aim to investigate XIAP expression in primary pancreatic carcinoma samples and to correlate its expression with clinical parameters to further explore the role of XIAP in pancreatic cancer.
Clinically, primary or acquired resistance of pancreatic cancer is a major cause of nonresponsiveness leading to treatment failure (Schneider et al., 2005) . This highlights the need for novel strategies to overcome resistance of pancreatic carcinoma, for example, by restoring defective cell death programs. By demonstrating that downregulation of XIAP increased TRAILinduced apoptosis in pancreatic carcinoma cells, our findings have important implications for the development of new strategies in cancer therapy. Thus, targeting XIAP could contribute to enhance the efficacy of TRAIL-based protocols in pancreatic cancer.
Materials and methods
Cell culture and retroviral transduction Colo357, PaTuII, PancTu1, ASPC1, DanG, Panc1, MiaPaCa2, BxPC3, SW850, Capan1, XUD and XS pancreatic carcinoma cells were kindly provided by RM Schmid (Technical University of Munich, Germany) or U Knippschild (University of Ulm, Germany). Cell lines were cultured in DMEM or RPMI1640 (Life Technologies, Inc., Eggenstein, Germany) supplemented with 10% fetal calf serum (FCS) (Biochrom, Berlin, Germany), 1 mM glutamine (Biochrom), 1% penicillin/streptavidin (Biochrom) and 25 mM HEPES (N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid) (Biochrom) as described previously (Fulda et al., 1997) .
To knockdown XIAP, shRNA targeting XIAP sequence 241 (gtggtagtcctgtttcagc) (Burstein et al., 2004) or sequence 1548 (tgtgctgaagcagttgaca) (Hao et al., 2004) corresponding to mRNA sequence were cloned into pRETRO-SUPER kindly provided by Dr Agami (The Netherlands Cancer Institute, Amsterdam, Netherlands) (Brummelkamp et al., 2002) . Besides empty vector control, a nonsense RNAi sequence, which was directed against a sequence with no corresponding part in the human genome (gatcatgtagatacgctca), was used to control for unspecific effects of shRNA. All sequences were cloned downstream of the polymerase III Histone H1-RNA promotor as a short-hairpin structure using restriction enzymes HindIII and BglII and controlled by sequencing. After selecting the transfected packaging cell line PT67 (BD Biosciences, Heidelberg, Germany) with 1 mg/ml puromycin (BD Biosciences) for 10 days, virus-containing supernatant was filtered and transferred to PancTu1, PaTuII or Colo357 cells followed by spin transduction in the presence of 1 mg/ml polybrene. Stable bulk cultures were generated by selection with 2 mg/ml puromycin, and downregulation of XIAP protein was controlled by Western blot.
Western blot analysis
Western blot analysis was performed as described previously (Fulda et al., 1997) using mouse anti-caspase-8 monoclonal antibody (1:1000; ApoTech Corporation, Epalinges, Switzerland), rabbit anti-caspase-3 polyclonal antibody (1:1000; Cell Signaling, Beverly, MA, USA), rabbit anti-caspase-9 polyclonal antibody (1:1000; BD Biosciences), mouse anti-XIAP monoclonal antibody (1:1000; clone 28; BD Biosciences), rabbit anti-cIAP2 polyclonal antibody (1:1000; R&D Systems, Inc., Wiesbaden, Germany), rabbit anti-survivin polyclonal antibody (1:1000; R&D Systems, Inc.), mouse anti-Smac monoclonal antibody (1:1000, BD Biosciences), rabbit antiBid polyclonal antibody (R&D Systems, Inc.), rabbit anti-PARP polyclonal antibody (1:5000, Roche Diagnostics, Mannheim, Germany) or mouse anti-b-actin monoclonal antibody (1:5000; Sigma, Steinheim, Germany) followed by goat-anti-mouse IgG or goat-anti-rabbit IgG conjugated to horseradish peroxidase (1:5000; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Enhanced chemiluminescence was used for detection (Amersham Bioscience, Freiburg, Germany). b-Actin was used as loading control. All Western blots shown are representative of at least three independent experiments.
Determination of apoptosis, cell viability and clonogenic survival For determination of apoptosis or cell viability, cells were cultured at 0.5 Â 10 5 cells/cm 2 . Apoptosis was determined by fluorescence-activated cell-sorting analysis (FACScan, BD Biosciences) of DNA fragmentation of propidium iodidestained nuclei as described previously (Fulda et al., 1997) . After stimulation with TRAIL (R&D Systems, Inc.) or agonistic anti-CD95 (APO-1) antibody (Trauth et al., 1989) and protein A (5 ng/ml; Sigma), cell viability was assessed by MTT assay according to the manufacturer's instructions (Roche Diagnostics). For clonogenic assay, cells were seeded as single cells (0.05 Â 10 5 cells/cm 2 ) in six-well plates for 24 h. Afterwards, cells were treated with TRAIL for 24 h, before the medium was exchanged and cells were recovered for additional 6 days in complete medium before staining with 0.75% crystal violet, 50% ethanol, 0.25% NaCl and 1.57% formaldehyde.
Determination of mitochondrial membrane potential and cytochrome c release CMXRos (1 mM; Molecular Probes, Karlsruhe, Germany) was used to measure the mitochondrial transmembrane potential. Cells were incubated for 30 min at 371C in the presence of the TRAIL-induced apoptosis in pancreatic cancer M Vogler et al fluorochrome and immediately analysed by flow cytometry.
CMXRos was recorded in fluorescence 3. Cytochrome c release was determined in permeabilized cells using mouse anti-cytochrome c monoclonal antibody (BD Biosciences) as previously described (Mohr et al., 2004) .
Caspase activity Caspase-3 activity was determined using a fluorimetric substrate for caspase-3 according to the manufacturer's instructions (Roche Diagnostics). Caspase activity was measured at 535 nm using 1420 Victor Multilabel Counter (PerkinElmer, Boston, MA, USA).
TRAIL-receptor staining
To determine TRAIL receptor expression PaTuII and PancTu1, cells were incubated with mouse anti-TRAIL-R1, mouse anti-TRAIL-R2, mouse anti-TRAIL-R3 or mouse anti-TRAIL-R4 (all ApoTech Corporation, Epalinges, Switzerland) antibody for 30 min at 41C, washed in PBS containing 1% FCS, incubated with rabbit anti-mouse-F(ab 0 ) 2 IgG/Biotin (BD Biosciences) for 20 min at 41C in the dark, washed in PBS containing 1% FCS, incubated with streptavidin-PE (BD Biosciences) for 20 min at 41C in the dark and analysed by flow cytometry.
Statistical analysis
Statistical significance was assessed by Student's t-tests (twotailed distribution, two-sample unequal variance).
